Pharming Group N.V.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $135.1m $169.0m $185.7m $198.9m $205.6m $245.3m $297.2m $376.1m
Cost of Goods and Services Sold $109.4m $21.4m $20.6m $21.1m $17.6m $25.2m $35.4m $45.5m
Cost Of Revenue $109.4m $21.4m $20.6m $21.1m $17.6m $25.2m $35.4m $45.5m
Reconciled Cost Of Revenue $11.5m $18.4m $28.7m $43.5m
Gross Profit $113.0m $147.7m $165.1m $177.7m $188.1m $220.1m $261.8m $330.6m
Research and development ($28.9m) $28.4m $33.7m $70.4m $52.5m $68.9m $83.1m $100.4m
Operating expenses:
Other Operating Costs ($75.6m) ($87.2m) ($100.0m) ($166.8m) ($184.3m) ($248.8m) ($272.6m) ($311.3m)
Other Operating Expenses $49.7m $76.8m $73.7m $82.7m
EBIT $20.3m ($6.0m) $245k $23.6m
Additional Financial Items
General and administrative ($12.2m) $18.9m $21.1m $37.0m $46.0m $55.9m $70.7m $80.0m
Applicable Tax Rate $0
Average Effective Tax Rate $1
Depreciation Right of Use Assets $1.5m $1.8m $2.8m $3.0m $3.7m $3.4m $3.0m
Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill $732k $0 ($5.0m) $0 $253k $0
Other Income $684k $435k $1.6m $2.6m $14.5m $23.3m $2.2m $6.5m
Profit Loss Attributable To Noncontrolling Interests ($313k)
Profit Loss Attributable To Owners Of Parent $2.9m
Profit Loss Before Tax $857k $46.7m $38.6m $23.1m $15.0m ($12.0m) ($8.5m) $12.8m
Profit Loss From Operating Activities $38.0m $60.9m $66.7m $13.6m $18.2m ($5.4m) ($8.6m) $25.8m
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method $0 $229k $317k $694k ($1.1m) ($289k) ($1.8m) $623k
Tax Rate Effect Of Foreign Tax Rates ($0)
Marketing and sales ($34.5m) ($39.9m) ($45.2m) ($59.4m) ($85.8m) ($124.0m) ($118.8m) ($131.0m)
Operating profit / (loss) $38.0m $60.9m $66.7m $13.6m $18.2m ($5.4m) ($8.6m) $25.8m
Fair value gain (loss) on revaluation ($495k) ($209k) $60k $114k ($1.2m) ($930k) $5.0m $2.3m
Other finance income $18k $1.0m $626k $14.9m $4.5m $3.7m $6.8m $2.2m
Share of net profits / (loss) in associates using the equity method $0 $229k $317k $694k ($1.1m) ($289k) ($1.8m) $623k
Profit / (loss) for the year $25.0m $36.2m $33.0m $16.0m $13.7m ($10.5m) ($11.8m) $2.5m
Equity holders of the parent ($10.5m) ($11.8m) $2.9m
Non-controlling interests $0 $0 ($313k)
Amortization $4.3m $5.6m $6.0m $6.3m
Amortization Of Intangibles Income Statement $4.3m $5.6m $6.0m $6.3m
Depreciation Amortization Depletion Income Statement $7.2m $9.2m $9.4m $9.2m
Depreciation And Amortization In Income Statement $7.2m $9.2m $9.4m $9.2m
Depreciation Income Statement $2.9m $3.5m $3.3m $2.9m
Diluted EPS $0.19 ($0.15) ($0.16) $0.04
Diluted NI Availto Com Stockholders $13.7m ($10.5m) ($11.8m) $2.9m
Earnings From Equity Interest $0 $229k $317k $694k ($1.1m) ($289k) ($1.8m) $623k
Gain On Sale Of Business $12.2m $0 $0
Gain On Sale Of PPE $0 $21.3m $0 $0
Gain On Sale Of Security $3.2m ($3.9m) $7.0m ($4.9m)
Impairment Of Capital Assets $4.4m $4.7m $5.0m $491k
Interest Income $85k $3.7m $4.9m $2.2m
Interest Income Non Operating $85k $3.7m $4.9m $2.2m
Minority Interests $0 $0 $313k
Net Income From Continuing And Discontinued Operation $13.7m ($10.5m) ($11.8m) $2.9m
Net Income From Continuing Operation Net Minority Interest $13.7m ($10.5m) ($11.8m) $2.9m
Net Interest Income ($5.4m) ($2.4m) ($5.1m) ($8.7m)
Normalized EBITDA $22.5m ($2.8m) $14.4m $36.3m
Normalized Income $3.6m ($21.7m) ($13.3m) $4.0m
Other Gand A $14.7m $15.0m $17.8m $18.3m
Reconciled Depreciation $13.2m $15.9m $16.1m $11.2m
Restructuring And Mergern Acquisition $0 $0
Salaries And Wages $47.7m $65.7m $74.3m $92.5m
Selling General And Administration $68.9m $87.5m $99.2m $117.4m
Special Income Charges $7.9m $16.6m ($5.0m) $3.4m
Tax Effect Of Unusual Items $971k $1.5m $503k ($385k)
Tax Provision $10.5m $5.6m $7.1m $1.3m ($1.5m) $3.3m $10.3m
Tax Rate For Calcs $0 $0 $0 $0
Total Unusual Items $11.1m $12.7m $1.9m ($1.5m)
Total Unusual Items Excluding Goodwill $11.1m $12.7m $1.9m ($1.5m)
Pre-Tax Income $857k $46.7m $38.6m $23.1m $15.0m ($12.0m) ($8.5m) $12.8m
Net Income $13.7m ($10.5m) ($11.8m) $2.9m
Net Income Continuous Operations $25.0m $36.2m $33.0m $16.0m $13.7m ($10.5m) ($11.8m) $2.5m
Net Income Including Noncontrolling Interests $25.0m $36.2m $33.0m $16.0m $13.7m ($10.5m) ($11.8m) $2.5m
Basic Earnings (Loss) Per Share $0.04 $0.06 $0.05 $0.03 $0.02 ($0.02) ($0.02) $0.00
Diluted Earnings (Loss) Per Share $0.04 $0.05 $0.05 $0.02 $0.02 ($0.02) ($0.02) $0.00
Basic Average Shares $65.1m $67.5m $68.8m $71.3m
Diluted Average Shares $72.0m $67.5m $68.8m $71.3m
Current Tax Expense (Income) $4.3m $2.4m $97k $3.8m $5.3m $9.3m $7.7m
Depreciation And Amortisation Expense $4.5m $5.3m $6.4m
Employee Benefits Expense $35.8m $45.0m $60.8m $68.3m $92.5m $104.2m $127.4m
Expense From Share-Based Payment Transactions With Employees $4.4m $7.4m $9.1m $6.4m $9.3m $11.3m $13.8m
Finance Costs $0 $65k $94k $105k $134k $56k $196k
Other Finance Cost $15.3m $29.2m $6.2m $5.5m $9.1m $9.9m $18.1m
Postemployment Benefit Expense Defined Benefit Plans $1.6m $1.6m $2.2m $2.3m $3.0m $3.6m $4.6m
Costs of sales ($22.2m) ($21.4m) ($20.6m) ($21.1m) ($17.6m) ($25.2m) ($35.4m) ($45.5m)
Other finance expenses ($36.7m) ($15.3m) ($29.2m) ($6.2m) ($5.5m) ($9.1m) ($9.9m) ($18.1m)
Finance (cost) / gain, net ($37.1m) ($14.5m) ($28.5m) $8.8m ($2.2m) ($6.3m) $1.9m ($13.6m)
Interest Expense $0 $5.4m $6.0m $8.7m $10.7m
Interest Expense On Lease Liabilities $662k $670k $795k $622k $1.1m $1.0m $1.0m
Income Tax Expense Continuing Operations $10.5m $5.6m $7.1m $1.3m ($1.5m) $3.3m $10.3m
Income tax (expense) / credit $24.1m ($10.5m) ($5.6m) ($7.1m) ($1.3m) $1.5m ($3.3m) ($10.3m)
General And Administrative Expense $62.4m $80.7m $92.1m $110.8m
Interest Expense Non Operating $0 $5.4m $6.0m $8.7m $10.7m
Net Non Operating Interest Income Expense ($5.4m) ($2.4m) ($5.1m) ($8.7m)
Operating Expense $178.2m $242.4m $265.5m $309.8m
Other Income Expense $10.5m $12.7m $259k $704k
Other Non Operating Income Expenses $507k $286k $71k $1.6m
Selling And Marketing Expense $6.4m $6.8m $7.1m $6.7m
Total Expenses $195.8m $267.6m $300.9m $355.3m
Total Other Finance Cost $105k $134k $1.2m $196k